• Forte Biosciences requested Nasdaq suspend trading and delist its shares following completion of its merger on Aug. 27, 2026.
• Nasdaq is expected to file Form 25 to remove the stock from listing and deregister it under Exchange Act Section 12(b).
• A Form 15 filing is planned to terminate registration under Section 12(g) and suspend SEC reporting duties under Sections 13 and 15(d).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-034698), on August 27, 2026, and is solely responsible for the information contained therein.